Tag: AbbVie Inc (ABBV)

URGENT BREAKING NEWS

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease. The drugs in question belong to AbbVie (ABBV) with some...

Read More

October 22, 2015

0

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations,...

Read More

January 4, 2016

0

Prohost Letter #392

Prohost Letter #392 February 28, 2016 -  How could it be possible for any genius to make intelligent guesses about the market's next moves when highly regarded experts, including Nobel Prize winners in economics, remained quizzical about the recent horrifying...

Read More

February 29, 2016

0

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

Juno Therapeutics (JUNO)  is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize  Juno CD19 program outside North America and China ....

Read More

April 13, 2016

0

URGENT BREAKING NEWS

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease. The drugs in question belong to AbbVie (ABBV) with some...

Read More

October 22, 2015

0

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations,...

Read More

January 4, 2016

0

Prohost Letter #392

Prohost Letter #392 February 28, 2016 -  How could it be possible for any genius to make intelligent guesses about the market's next moves when highly regarded experts, including Nobel Prize winners in economics, remained quizzical about the recent horrifying...

Read More

February 29, 2016

0

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY) , but just a few may know anything about CytomX Therapeutics (CTMX ) , or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads...

Read More

March 23, 2017

0

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

Juno Therapeutics (JUNO)  is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize  Juno CD19 program outside North America and China ....

Read More

April 13, 2016

0

Prohost Letter #407

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES   On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD),...

Read More

April 20, 2017

0

Search ProhostBiotech